HighPoint Advisor Group LLC Has $2.12 Million Stake in CVS Health Co. (NYSE:CVS)

HighPoint Advisor Group LLC decreased its position in CVS Health Co. (NYSE:CVS - Free Report) by 18.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 47,299 shares of the pharmacy operator's stock after selling 10,401 shares during the quarter. HighPoint Advisor Group LLC's holdings in CVS Health were worth $2,123,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Ridgewood Investments LLC boosted its position in shares of CVS Health by 255.7% during the 4th quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator's stock valued at $28,000 after purchasing an additional 450 shares in the last quarter. Stonebridge Financial Group LLC acquired a new stake in CVS Health during the fourth quarter valued at approximately $28,000. Hopwood Financial Services Inc. bought a new stake in CVS Health during the fourth quarter worth approximately $29,000. Legacy Investment Solutions LLC acquired a new position in CVS Health in the third quarter worth approximately $31,000. Finally, Financial Perspectives Inc increased its holdings in shares of CVS Health by 137.5% in the fourth quarter. Financial Perspectives Inc now owns 805 shares of the pharmacy operator's stock valued at $36,000 after buying an additional 466 shares in the last quarter. 80.66% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at CVS Health

In related news, SVP James David Clark sold 7,513 shares of CVS Health stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total value of $498,487.55. Following the transaction, the senior vice president now owns 8,394 shares in the company, valued at $556,941.90. This trade represents a 47.23 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Michael F. Mahoney purchased 30,000 shares of the firm's stock in a transaction on Tuesday, February 18th. The shares were purchased at an average price of $66.70 per share, with a total value of $2,001,000.00. Following the completion of the acquisition, the director now directly owns 39,356 shares of the company's stock, valued at approximately $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.24% of the stock is owned by corporate insiders.

Remove Ads

CVS Health Stock Down 5.9 %

NYSE:CVS traded down $3.97 during trading hours on Friday, reaching $63.54. The company's stock had a trading volume of 13,291,234 shares, compared to its average volume of 11,586,970. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.81 and a quick ratio of 0.60. The company has a market cap of $80.11 billion, a price-to-earnings ratio of 17.36, a price-to-earnings-growth ratio of 0.98 and a beta of 0.57. CVS Health Co. has a one year low of $43.56 and a one year high of $74.85. The business's 50-day moving average is $63.47 and its 200-day moving average is $58.01.

CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. Equities research analysts predict that CVS Health Co. will post 5.89 EPS for the current year.

CVS Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd will be given a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.19%. The ex-dividend date is Tuesday, April 22nd. CVS Health's dividend payout ratio is 72.68%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. JPMorgan Chase & Co. lifted their target price on CVS Health from $80.00 to $81.00 and gave the stock an "overweight" rating in a report on Tuesday, February 18th. Leerink Partners upgraded CVS Health from a "market perform" rating to an "outperform" rating and boosted their price objective for the stock from $55.00 to $75.00 in a report on Thursday, February 13th. Wolfe Research raised their target price on shares of CVS Health from 67.00 to 70.00 and gave the stock an "overweight" rating in a report on Tuesday, February 11th. Leerink Partnrs upgraded shares of CVS Health from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 12th. Finally, Barclays lifted their price objective on shares of CVS Health from $71.00 to $73.00 and gave the stock an "overweight" rating in a research report on Thursday, February 13th. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $70.39.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.